PMID- 35175152
OWN - NLM
STAT- MEDLINE
DCOM- 20220224
LR  - 20220531
IS  - 1365-2060 (Electronic)
IS  - 0785-3890 (Print)
IS  - 0785-3890 (Linking)
VI  - 54
IP  - 1
DP  - 2022 Dec
TI  - Coeliac disease in the COVID-19 pandemic: does HLA have a protective effect?
PG  - 617-621
LID - 10.1080/07853890.2022.2039955 [doi]
AB  - BACKGROUND: The coronavirus disease 2019 (COVID-19), an acute respiratory disease 
      caused by a novel coronavirus (SARS-CoV-2), is emerging as a worldwide public 
      health emergency. Several scientific contributions reported the potential 
      relevance of human leukocyte antigen (HLA) polymorphism and susceptibility to 
      viruses, such as SARS-CoV. In our study, we examined a population of coeliac 
      subjects presenting the HLA haplotype DQ2 and/or DQ8. Our aim was to evaluate 
      whether HLA DQ2 and/or DQ8 haplotype play a role in SARS-CoV-2-infection. The aim 
      was also to evaluate the difficulty in following the gluten-free diet due to all 
      the adversities produced by the pandemic, such as the food supply disruption, and 
      the difficulties in managing the clinical follow-up. METHODS: 191 consecutive 
      coeliac patients completed a questionnaire on their current clinical status, 
      psychological effects, and management of the gluten-free diet experienced during 
      the COVID-19 pandemic and questions regarding possible SARS-CoV-2 infection. 
      RESULTS: Out of the 191 patients who participated in the study, 42 were 
      full-blown coeliac and 149 were in remission. From the answers provided, 84.8% of 
      patients declared that they no longer consider themselves vulnerable to COVID-19 
      as they suffer from coeliac disease; 94.2% of patients did not encounter any 
      difficulties in managing the gluten-free diet or in acquiring specific foods and 
      64.9% of patients in our study underwent diagnostic testing for SARS-CoV-2. Out 
      of this number, 31.5% did so due to contacts with subjects affected by COVID-19, 
      26.6% for work related reasons, 11.3% due to flu-like symptoms and 30.6% for 
      other reasons. Only 5.8% of the enrolled patients received a diagnosis of 
      COVID-19. Out of all the patients in our population who were diagnosed with 
      COVID-19, 94.8% developed no symptoms and none of them needed hospitalization or 
      intensive care. CONCLUSION: The hypothesis that the HLADQ2 and/or DQ8 haplotype 
      plays a protective role against SARS-CoV-2 infection, as against other viral 
      infections, is intriguingly suggestive.KEY MESSAGESCOVID-19 as a public health 
      emergency;SARS-CoV-2 and possible complications in coeliac disease;Role of HLA 
      DQ2 and/or DQ8 in SARS-CoV-2 infection.
FAU - Greco, N
AU  - Greco N
AD  - Department of Translational and Precision Medicine, Sapienza University of Rome, 
      Rome, Italy.
FAU - Meacci, A
AU  - Meacci A
AD  - Department of Translational and Precision Medicine, Sapienza University of Rome, 
      Rome, Italy.
FAU - Mora, B
AU  - Mora B
AD  - Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
FAU - Vestri, A
AU  - Vestri A
AD  - Department of Public Health and Infectious Diseases, Sapienza University of Rome, 
      Rome, Rome, Italy.
FAU - Picarelli, A
AU  - Picarelli A
AD  - Department of Translational and Precision Medicine, Sapienza University of Rome, 
      Rome, Italy.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ann Med
JT  - Annals of medicine
JID - 8906388
RN  - 0 (HLA-DQ Antigens)
RN  - 0 (HLA-DQ2 antigen)
RN  - 0 (HLA-DQ8 antigen)
SB  - IM
MH  - *COVID-19/complications/genetics
MH  - *Celiac Disease/diagnosis/epidemiology/genetics
MH  - Critical Care
MH  - HLA-DQ Antigens/*genetics
MH  - Haplotypes
MH  - Humans
MH  - Pandemics
MH  - SARS-CoV-2
PMC - PMC8856018
OTO - NOTNLM
OT  - COVID-19
OT  - Human leukocyte antigen (HLA)
OT  - SARS-CoV-2
OT  - autoimmune disease
OT  - coeliac disease
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2022/02/18 06:00
MHDA- 2022/02/25 06:00
PMCR- 2022/02/17
CRDT- 2022/02/17 12:19
PHST- 2022/02/17 12:19 [entrez]
PHST- 2022/02/18 06:00 [pubmed]
PHST- 2022/02/25 06:00 [medline]
PHST- 2022/02/17 00:00 [pmc-release]
AID - 2039955 [pii]
AID - 10.1080/07853890.2022.2039955 [doi]
PST - ppublish
SO  - Ann Med. 2022 Dec;54(1):617-621. doi: 10.1080/07853890.2022.2039955.